Premium
Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk‐adapted protocols
Author(s) -
Motlló Cristina,
Ribera JosepMaría,
Morgades Mireia,
Granada Isabel,
Montesinos Pau,
GonzálezCampos José,
FernándezAbellán Pascual,
Tormo Mar,
Bethencourt Concepción,
Brunet Salut,
HernándezRivas JesúsMaría,
Moreno MaríaJosé,
Sarrà Josep,
del Potro Eloy,
Barba Pere,
Bernal Teresa,
Grande Carlos,
Grau Javier,
Cervera José,
Feliu Evarist
Publication year - 2014
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.28950
Subject(s) - karyotype , medicine , lymphoblastic leukemia , oncology , leukemia , pediatrics , genetics , chromosome , biology , gene
BACKGROUND The karyotype is a predictor of outcomes in adults with acute lymphoblastic leukemia (ALL). The unfavorable prognostic significance of complex karyotype (CK) has been reported, whereas the prognostic relevance of monosomal karyotype (MK) has not been consistently evaluated. We aimed to assess the prognostic value of CK and MK in adults with ALL treated with risk‐adapted protocols of the Spanish PETHEMA Group. METHODS The karyotypes of 881 adult ALL patients treated according to the protocols of the PETHEMA Group between 1993 and 2012 were centrally reviewed. CK and MK were assessed according to Moorman's criteria, and Breem's criteria, respectively. Specific analyses according to the risk groups and to the presence of t(9:22) were performed. RESULTS Of 364 evaluable patients 33 (9.2%) had CK, and 68 of 535 evaluable patients (12.8%) had MK. Complete remission rate, remission duration, and overall survival were not significantly different according to the presence of CK or MK in the whole series, according to the B or T lineage, in the high‐risk group, or in patients with t(9;22), regardless of imatinib treatment, and in patients who received chemotherapy alone or chemotherapy followed by stem cell transplantation CONCLUSIONS Our study shows that CK and MK were not associated with a worse prognosis in adult patients with ALL treated with risk‐adapted or subtype‐oriented protocols. In patients with Ph+ ALL, MK did not have an impact on prognosis irrespective of imatinib treatment. Cancer . © 0000 American Cancer Society Cancer 2014;120:3958–3964. © 2014 American Cancer Society .